Finding New Ways to Treat Kidney Disease

Update item information
Identifier finding_new_ways_to_treat_kidney_disease
Title Finding New Ways to Treat Kidney Disease
Creator Kohan, D.; Internal Medicine/Nephrology; School of Medicine; University of Utah Health
Subject Diffusion of Innovation; Kidney Diseases; Renal Insufficiency, Chronic; Receptor, Endothelin A; Endothelin-1; Endothelin-1; Autoimmune Diseases; Inflammation; Hypertension; Knowledge Discovery
Keyword Health and Disease
Image Caption Blocking ETA with a drug called atrasentan slows diabetic CKD progression
Description Chronic kidney disease affects millions of people in the U.S. and worldwide; however, current treatments are not highly effective. Many factors contribute to chronic kidney disease, including diabetes, hypertension, autoimmune disorders, and others. Research in the lab of University of Utah Health investigator Donald Kohan, MD, PhD, used genetically engineered mice to help identify a peptide, endothelin-1, and its receptor, ETA, as key regulators of blood pressure and kidney function in health. Kohan and colleagues also helped determine that kidney ET-1 production is increased in many kidney diseases and, through activation of ETA receptors on most kidney cell types, leads to inflammation, scarring, and decreased kidney function. Together with national and international collaborators, they have translated these studies into clinical trials demonstrating that blocking the ETA receptor protects kidney function in individuals with type 2 diabetes mellitus. These trials with ETA receptor antagonists are now being extended into other forms of chronic kidney disease. Targeting the endothelin-1/ETA receptor system represents a promising approach to the treatment of chronic kidney disease.
Relation is Part of 2019
Publisher Spencer S. Eccles Health Sciences Library, University of Utah
Date Digital 2021
Date 2019
Type Image
Format image/jpeg
Rights Management Copyright © 2021, University of Utah, All Rights Reserved
Language eng
ARK ark:/87278/s6354jqq
References 1.) Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention. Ahn D, Ge Y, Stricklett PK, Gill P, Taylor D, Hughes AK, Yanagisawa M, Miller L, Nelson RD, Kohan DE. J Clin Invest. 2004 Aug;114(4):504-511. 2.) Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. Kohan DE, Pritchett Y, Molitch M, Wen S, Garimella T, Audhya U, Andress DL. J Am Soc Nephrol. 2011 Apr;22(4):763-772. 3.) Regulation of blood pressure and salt homeostasis by endothelin. Kohan DE, Inscho E, Rossi N, Pollock DM. Physiol Rev. 2011 Jan;91(1):1-77. 4.) Atrasentan and renal events in type 2 diabetes with chronic kidney disease (SONAR): a double-blind, randomized, placebo-controlled trial. Heerspink HJ, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou F-F, Kitzman DW, Kohan DE, Makino H, McMurray J, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D. Lancet. 2019 May;393(10184):1937-1947.
Setname ehsl_50disc
ID 1697481
Reference URL